VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
Copyright 2022, Business Wire.
news
2022-10-17 12:00:00

October 17, 2022 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI's President and CEO, and David E. Anderson, Ph.D., VBI's Chief Scientific Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on Tuesday, October 18, 2022.
